Literature DB >> 10208927

Phosphorylation of nonstructural 5A protein of hepatitis C virus: HCV group-specific hyperphosphorylation.

M Hirota1, S Satoh, S Asabe, M Kohara, K Tsukiyama-Kohara, N Kato, M Hijikata, K Shimotohno.   

Abstract

We previously showed that two proteins with molecular weights of 56 and 58 kDa are produced from nonstructural protein 5A (NS5A) derived from hepatitis C virus (HCV)-1b genotype. The 56-kDa protein is phosphorylated at serine residues in NS5A, including those located in the C-terminal region of NS5A, while the 58-kDa protein, the hyperphosphorylated form of the 56-kDa protein, is phosphorylated at serine residues in the central region. This hyperphosphorylation is dependent on the presence of HCV NS4A protein. To clarify whether NS4A-dependent phosphorylation also occurs in other HCV genotypes, phosphorylation of NS5A was analyzed by two-dimensional gel electrophoresis. Here, we report that NS5A from the HCV-2a genotype was phosphorylated. However, hyperphosphorylation of NS5A occurs in the HCV-1b genotype but not in the -2a genotype. This result suggests that modification of NS5A phosphorylation reflects the virological features of HCV and that there are physiological differences in the roles of differently phosphorylated NS5A between HCV genotypes. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10208927     DOI: 10.1006/viro.1999.9658

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  9 in total

1.  High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group.

Authors:  Y Shiratori; R Nakata; N Shimizu; H Katada; S Hisamitsu; E Yasuda; M Matsumura; T Narita; K Kawada; M Omata
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

2.  Caspase-mediated cleavage of eukaryotic translation initiation factor subunit 2alpha.

Authors:  S Satoh; M Hijikata; H Handa; K Shimotohno
Journal:  Biochem J       Date:  1999-08-15       Impact factor: 3.857

3.  Sequential Phosphorylation of Hepatitis C Virus NS5A Protein Requires the ATP-Binding Domain of NS3 Helicase.

Authors:  Chun-Chiao Yu; Pei-Chen Lin; Cho-Han Chiang; Shu-Tang Jen; Yen-Ling Lai; Shih-Chin Hsu; Lee-Chiang Lo; Jing-Jer Lin; Nei-Li Chan; Ming-Jiun Yu
Journal:  J Virol       Date:  2022-03-16       Impact factor: 6.549

Review 4.  Scotomas in molecular virology and epidemiology of hepatitis C virus.

Authors:  Yue Wang
Journal:  World J Gastroenterol       Date:  2013-11-28       Impact factor: 5.742

5.  Hepatitis C virus non-structural 5A protein can enhance full-length core protein-induced nuclear factor-kappaB activation.

Authors:  Qing-Jiao Liao; Lin-Bai Ye; Khalid Amine Timani; Ying-Long She; Xiao-Jun Yang; Li Ye; Zheng-Hui Wu
Journal:  World J Gastroenterol       Date:  2005-11-07       Impact factor: 5.742

6.  Hepatitis C virus NS5A binds to the mRNA cap-binding eukaryotic translation initiation 4F (eIF4F) complex and up-regulates host translation initiation machinery through eIF4E-binding protein 1 inactivation.

Authors:  Anju George; Swarupa Panda; Devika Kudmulwar; Salma Pathan Chhatbar; Sanjeev Chavan Nayak; Harinivas Harshan Krishnan
Journal:  J Biol Chem       Date:  2011-12-19       Impact factor: 5.157

7.  HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding.

Authors:  Guo-Zhong Gong; Yong-Fang Jiang; Yan He; Li-Ying Lai; Ying-Hua Zhu; Xian-Shi Su
Journal:  World J Gastroenterol       Date:  2004-08-01       Impact factor: 5.742

8.  High-throughput screening of the yeast kinome: identification of human serine/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein.

Authors:  Carlos Coito; Deborah L Diamond; Petra Neddermann; Marcus J Korth; Michael G Katze
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

9.  Calcium-dependent calpain proteases are implicated in processing of the hepatitis C virus NS5A protein.

Authors:  M Kalamvoki; P Mavromara
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.